
    
      This is a phase IIb clinical trial to evaluate safety and immuogenicity of Ad5-nCoV developed
      by Cansino and Beijing Institute of Biotechnology in health people aged 6 years old and
      above.

      The study will be double-blind, placebo-controlled trial with participants randomly allocated
      2:1 to placebo and experimental vaccine .

      The immunization schedule is two doses intramuscular injections (deltoid).
    
  